News brief
On 2026/9/24, Presspool reported that BigHat Biosciences, a US AI antibody design company, raised USD 75 million in Series C funding, led by DFJ Growth and Premji Invest.
Connected profiles
Explore
Sources · 1Sources & provenance
English text is maintained separately from the original record. Consult the original source before citing a fact.
- presspool.ai ↗Published Sep 24, 2026
Original source text
Names may use phonetic renderings when no English name is supplied. The original wording is retained below.
2026年9月24日，据Presspool报道，美国AI抗体设计公司BigHat Biosciences完成7500万美元C轮融资，由DFJ Growth与Premji Invest领投。